olanzapine induced tardive dyskinesia
Clicks: 2
ID: 160946
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #15 of 15 articles by views in european journal of language policy
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Olanzapine is considered to have significantly less risk of tardive dyskinesia (TD) compared to first generation antipsychotics. We describe two patients who developed TD after prolonged use of olanzapine. Both the patients received no medications prior to the treatment with olanzapine. They neither received any other medication along with olanzapine nor any injectible antipsychotics. In one patient, TD improved completely after withdrawal of olanzapine and treatment with clozapine, but recurred after a retrial of olanzapine. In the other patient, reduction of dose of olanzapine was tried without any success. Despite a substantially lower risk than first generation antipsychotics, TD is not entirely absent with olanzapine.
| Reference Key |
chakraborty2014medicalolanzapine
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Rudraprosad Chakraborty;Arunima Chatterjee;Suprakash Chaudhury |
| Journal | european journal of language policy |
| Year | 2014 |
| DOI |
10.4103/0975-2870.122790
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.